Filtered By:
Cancer: Leukemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38320 results found since Jan 2013.

Addressing Challenges in Chronic Lymphocytic Leukemia with Continuing Education: Impact on Practice Behaviors and Knowledge
Conclusions: Ongoing education on CLL can yield immediate and sustained gains in knowledge, competence, and performance, and improve the ability to provide individualized treatment for patients.DisclosuresVose: Kite Pharma: Research Funding; Legend Pharmaceuticals: Honoraria; Merck Sharp & Dohme Corp.: Research Funding; Novartis: Honoraria, Research Funding; Bristol Myers Squibb: Research Funding; Celgene: Research Funding; Abbvie: Honoraria; Seattle Genetics, Inc.: Research Funding; Incyte Corp.: Research Funding; Acerta Pharma: Research Funding; Epizyme: Honoraria; Roche: Honoraria. O'Brien: Acerta: Research Funding;...
Source: Blood - November 21, 2018 Category: Hematology Authors: Roc, A. C., Vose, J. M., O'Brien, S. M., Turell, W. Tags: 902. Health Services Research-Malignant Diseases Source Type: research

A Multimedia E-Book —A Story of Health: Filling a Gap in Environmental Health Literacy for Health Professionals
Author Affiliations open 1Western States Pediatric Environmental Health Specialty Unit, University of California San Francisco, San Francisco, California, USA; 2California Environmental Protection Agency, Oakland, California, USA; 3Collaborative on Health and the Environment, Bolinas, California, USA; 4Science and Environmental Health Network, Ames, Iowa, USA; 5Environmental Medicine Branch, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA PDF Version (3 MB) Summary About This Article Narrative approaches and storytelling are emerging a...
Source: EHP Research - August 1, 2016 Category: Environmental Health Authors: Web Admin Tags: Brief Communication August 2016 Source Type: research

Assessing Hematologist's Knowledge of the Use of Ibrutinib and Acalabrutinib in B-Cell Malignancies
Conclusions: This activity indicates there are significant gaps in knowledge and confidence as well as barriers impeding hem/onc ability to incorporate BTK inhibitors into the treatment plans for their patients with B-cell malignancies. There is sub-optimal awareness of differences between first and second generation BTK inhibitors as well as trial data for second generation BTK inhibitors. Additional education is needed to improve the knowledge and confidence of academic and community hem/onc specialists who care for patients with CLL and MCL so they are better equipped to utilize BTK inhibitors.DisclosuresFurman: Acerta:...
Source: Blood - November 21, 2018 Category: Hematology Authors: Willis, L., Tanzola, M., Furman, R. R. Tags: 902. Health Services Research-Malignant Diseases Source Type: research

Hematologists Demonstrate Sub-Optimal Knowledge of FLT3 Mutations in Acute Myeloid Leukemia
Conclusions: After decades of using the same initial treatment for AML, key advances have led to therapy changes for subsets of patients with AML such as those with FLT3 mutations. Gaps in clinical knowledge and competence for hem/onc practitioners were identified in this assessment.These deficiencies included testing for FLT3 mutations and integrating FLT3 inhibitors into therapy for the treatment of patients with AML. Additionally, the activity demonstrated gaps in the knowledge of testing recommendations and the practice of FLT3 mutation testing in all newly diagnosed AML patients. Additional education is needed to impr...
Source: Blood - November 21, 2018 Category: Hematology Authors: Willis, L., Fagerlie, S. R. Tags: 902. Health Services Research-Malignant Diseases Source Type: research

Addressing Challenges in Living with AML: Impact of Video-Based Patient Education on Knowledge and Behavior
Conclusions: Education on AML specifically catered to patients and their families can yield immediate and sustained gains in knowledge and behavior, which may improve their adherence to treatment, quality of life, and patient outcomes.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Roc, A. C., Steensma, D. P., Rajotte, M., Turell, W. Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research

Primary myelofibrosis: 2013 update on diagnosis, risk‐stratification, and management
Disease overviewPrimary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell‐derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DiagnosisDiagnosis is based on bone marrow morphology. The presence of fibrosis, JAK2/MPL mutation, or +9/13q− cytogenetic abnormality is supportive but not essential for diagnosis. Prefibrotic PMF mimics essential thrombocythemia in its presentation and the distinction is prognostically relevan...
Source: American Journal of Hematology - January 24, 2013 Category: Hematology Authors: Ayalew Tefferi Tags: A Continuing Medical Education Series Source Type: research

Acute myeloid leukemia: 2013 update on risk‐stratification and management
Disease overviewAcute myeloid leukemia (AML) results from accumulation of abnormal blasts in the marrow. These cells interfere with normal hematopoiesis, can escape into the peripheral blood, and infiltrate CSF and lung. It is likely that many different mutations, epigenetic aberrations, or abnormalities in micro RNA expression can produce the same morphologic disease with these differences responsible for the very variable response to therapy, which is AMLs principal feature. DiagnosisThis rests on demonstration that the marrow or blood has > 20% blasts of myeloid lineage. Blast lineage is assessed by multiparamete...
Source: American Journal of Hematology - March 25, 2013 Category: Hematology Authors: Elihu H. Estey Tags: A Continuing Medical Education Series Source Type: research

Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk‐stratification, and management
Disease OverviewPolycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) primarily characterized by erythrocytosis and thrombocytosis, respectively. Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus and a small risk of disease progression into acute myeloid leukemia or myelofibrosis. DiagnosisAlmost all patients with PV harbor a JAK2 mutation. When PV is suspected, the presence of a JAK2 mutation highly suggests the diagnosis and its absence, combined with normal or increased serum erythropoietin level, exclu...
Source: American Journal of Hematology - May 21, 2013 Category: Hematology Authors: Ayalew Tefferi Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management
Disease overview:Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs. Diagnosis:The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC expression of CD25 and/or CD2, and presence of KITD816V. Risk stratification:The 2008 World Health Organization (WHO) classification of SM has been shown to be prognostically relevant. Classification of SM patients into indolent (SM), aggressive SM (ASM), SM associated with a clonal non‐M...
Source: American Journal of Hematology - May 30, 2013 Category: Hematology Authors: Animesh Pardanani Tags: A Continuing Medical Education Series Source Type: research

Therapy-related chronic myelomonocytic leukemia
Source: Blood - October 17, 2013 Category: Hematology Tags: CME article CONTINUING MEDICAL EDUCATION (CME) QUESTIONS Source Type: research

Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management
Disease overviewChronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder that is classified as a myelodysplastic/myeloproliferative neoplasm by the 2008 World Health Organization classification of hematopoietic tumors. It is characterized by absolute monocytosis (>1 × 109/L) in the peripheral blood that persists for at least 3 months. DiagnosisThe diagnosis of CMML rests on a combination of morphologic, histopathologic and chromosomal abnormalities in the bone marrow. It is important to exclude other myeloproliferative neoplasms and infectious/autoimmune conditions that can cause monocyto...
Source: American Journal of Hematology - October 24, 2013 Category: Hematology Authors: Sameer A. Parikh, Ayalew Tefferi Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management
 Disease Overview: Chronic neutrophilic leukemia (CNL) is a myeloproliferative neoplasm characterized by sustained, mature neutrophilic leukocytosis, splenomegaly, and bone marrow granulocytic hyperplasia.  Diagnosis: Key diagnostic criteria include leukocytosis of >25 × 109/l (of which >80% are neutrophils) with <10% and <1% circulating immature granulocytes and myeloblasts, respectively. There should be no dysplasia, monocytosis, molecular evidence of BCR‐ABL1, PDGFRA, PDGFRB, or FGRF1 rearrangements and no identifiable cause for physiologic neutrophilia or, if present, demonstration of myeloid clo...
Source: American Journal of Hematology - May 20, 2014 Category: Hematology Authors: Michelle A. Elliott, Ayalew Tefferi Tags: A Continuing Medical Education Series Source Type: research

Acute myeloid leukemia: 2014 Update on risk‐stratification and management
Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML therapy. The fundamental decision in AML then becomes whether to recommend standard or investigational treatment. This decision must rest on the likely outcome of standard treatment. Hence we review factors that predict treatment related mortality and resistance to therapy, the latter the principal cause of failure even in patients aged 70 or above. We emphasize the limitations of prediction of resistance based only on pre‐treatment factors and stress the need to incorporate post‐treatment factors, for example indicators of minimal...
Source: American Journal of Hematology - October 16, 2014 Category: Hematology Authors: Elihu H. Estey Tags: A Continuing Medical Education Series Source Type: research

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR‐ABL1 fusion oncogene, which in turn translates into...
Source: American Journal of Hematology - January 22, 2016 Category: Hematology Authors: Elias Jabbour, Hagop Kantarjian Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS ‐T): 2017 update on diagnosis, risk‐stratification, and management
Abstract Disease OverviewRing sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T). DiagnosisMDS‐RS is a lower risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥15% BM RS (≥5% in the presence of SF3B1 mutations)....
Source: American Journal of Hematology - February 10, 2017 Category: Hematology Authors: Mrinal M. Patnaik, Ayalew Tefferi Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research